Suppr超能文献

尿激酶型纤溶酶原激活剂的去甲基化相关激活参与前列腺癌进展。

Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.

作者信息

Pulukuri Sai Murali Krishna, Estes Norman, Patel Jitendra, Rao Jasti S

机构信息

Department of Cancer Biology and Pharmacology, College of Medicine, University of Illinois at Peoria, Peoria, IL 61656, USA.

出版信息

Cancer Res. 2007 Feb 1;67(3):930-9. doi: 10.1158/0008-5472.CAN-06-2892.

Abstract

Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer. However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive. Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples. This aberrant expression is associated with cancer-linked demethylation of the uPA promoter. Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo. Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

摘要

据报道,包括前列腺癌在内的多种恶性肿瘤中尿激酶型纤溶酶原激活剂(uPA)的表达均有所增加。然而,uPA在前列腺癌中异常表达的机制仍不清楚。在此,我们发现,uPA在高比例的人类前列腺癌组织中异常表达,但在肿瘤匹配的非肿瘤相邻组织或良性前列腺增生样本中很少表达。这种异常表达与uPA启动子的癌症相关去甲基化有关。此外,用去甲基化抑制剂S-腺苷甲硫氨酸处理或稳定表达uPA短发夹RNA可显著抑制uPA在体外的表达和肿瘤细胞侵袭,以及在体内的肿瘤生长和肺转移发生率。总体而言,这些发现强烈表明,DNA去甲基化是uPA异常表达的常见机制,也是人类前列腺肿瘤恶性进展的关键促成因素。

相似文献

3
Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Exp Mol Pathol. 2013 Jun;94(3):458-65. doi: 10.1016/j.yexmp.2013.03.006. Epub 2013 Mar 27.
5
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Oncogene. 2013 May 2;32(18):2282-91, 2291.e1-7. doi: 10.1038/onc.2012.251. Epub 2012 Jul 16.
6
Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
J Biol Chem. 2004 Jul 23;279(30):31735-44. doi: 10.1074/jbc.M401669200. Epub 2004 May 18.
10
Amplification of urokinase gene in prostate cancer.
Cancer Res. 2001 Jul 15;61(14):5340-4.

引用本文的文献

6
Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.
Hum Genomics. 2016 Jul 25;10 Suppl 2(Suppl 2):18. doi: 10.1186/s40246-016-0071-5.
7
Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells.
Oncotarget. 2015 Sep 29;6(29):26960-70. doi: 10.18632/oncotarget.4745.
8
DNA Methylation and Flavonoids in Genitourinary Cancers.
Curr Pharmacol Rep. 2015 Apr 1;1(2):112-120. doi: 10.1007/s40495-014-0004-8.
9
10
Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease.
Biomol Ther (Seoul). 2012 May;20(3):245-55. doi: 10.4062/biomolther.2012.20.3.245.

本文引用的文献

2
Proteases and glioma angiogenesis.
Brain Pathol. 2005 Oct;15(4):327-41. doi: 10.1111/j.1750-3639.2005.tb00118.x.
6
Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Clin Cancer Res. 2005 Aug 15;11(16):5793-801. doi: 10.1158/1078-0432.CCR-04-2545.
7
DNA methylation and demethylation as targets for anticancer therapy.
Biochemistry (Mosc). 2005 May;70(5):533-49. doi: 10.1007/s10541-005-0147-7.
8
Functional epigenomics identifies genes frequently silenced in prostate cancer.
Cancer Res. 2005 May 15;65(10):4218-27. doi: 10.1158/0008-5472.CAN-04-4407.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验